scPharmaceuticals
scPharmaceuticals provides subcutaneous administration of therapies that have previously been limited to intravenous, or IV, delivery reducing overall healthcare costs and advances the quality and convenience of care.
The lead product Furoscix, is under development for treatment of worsening, or decompensated, heart failure outside of the inpatient setting.
